Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions

被引:1
|
作者
Kazarian, Austin G. [1 ]
Chawla, Neal S. [2 ]
Muddasani, Ramya [2 ]
Pal, Sumanta K. [2 ]
机构
[1] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, 1500 East Duarte Rd, Duarte, CA 91010 USA
关键词
Renal cell carcinoma; adjuvant chemotherapy; cytokines; molecular targeted therapy; precision medicine; BLIND PHASE-III; HIGH-RISK; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; TRIAL; INTERLEUKIN-2; STAGE; RECURRENCE; SURVIVAL; IMMUNOTHERAPY;
D O I
10.3233/KCA-200105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, incredible progress has been made in the treatment of metastatic renal cell carcinoma, with a paradigm shift from the use of cytokines to tyrosine kinase inhibitors, and more recently, immune checkpoint inhibitors (ICIs). Despite advances in the metastatic setting, effective therapies in the adjuvant setting are a largely unmet need. Currently, sunitinib (Sutent, Pfizer) is the only therapy for the adjuvant treatment of RCC included in the National Comprehensive Cancer Network guidelines, which was approved by the FDA based on the improvement in disease-free survival (DFS) seen in the S-TRAC trial. However, improvement in DFS has not translated into an overall survival (OS) benefit for patients at high-risk of relapse post-nephrectomy, illustrating the need for more effective therapies. This manuscript will highlight attributes of both historical and current drug trials and their implications on the landscape of adjuvant therapy. Additionally, we will outline strategies for selecting patients in whom treatment would be most beneficial, as optimal patient selection is a crucial step towards improving outcomes in the adjuvant setting. This is especially critical, given the financial cost and pharmacological toxicity of therapeutic agents. Furthermore, we will review the design of clinical trials including the value of utilizing OS as an endpoint over DFS. Finally, we will discuss how the incorporation of genomic data into predictive models, the use of more sensitive imaging modalities for more accurate staging, and more extensive surgical intervention involving lymph node dissection, may impact outcomes.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 50 条
  • [21] Cell therapy for heart disease: current status and future directions
    Kahlon, Arunpreet
    Vaidya, Gaurang
    Bolli, Roberto
    MINERVA CARDIOANGIOLOGICA, 2018, 66 (03): : 273 - 291
  • [22] Bone marrow cell therapy: Current status and future directions?
    Dawn, Buddhadeb
    VASCULAR PHARMACOLOGY, 2012, 56 (5-6) : 323 - 323
  • [23] Current Status and Future Directions of Proton Therapy for Head and Neck Carcinoma
    Lillo, Sara
    Mirandola, Alfredo
    Vai, Alessandro
    Camarda, Anna Maria
    Ronchi, Sara
    Bonora, Maria
    Ingargiola, Rossana
    Vischioni, Barbara
    Orlandi, Ester
    CANCERS, 2024, 16 (11)
  • [24] Combined modality therapy for carcinoma of the oesophagus: current status and future directions
    Burmeister, BH
    Smithers, BM
    Denham, JW
    MEDICAL JOURNAL OF AUSTRALIA, 1997, 167 (07) : 349 - 350
  • [25] Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
    Pal, Sumanta K.
    Haas, Naomi B.
    ONCOLOGIST, 2014, 19 (08): : 851 - 859
  • [26] Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma
    Nandagopal, Lakshminarayanan
    Naik, Gurudatta
    Sonpavde, Guru
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (01)
  • [27] Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma
    Lakshminarayanan Nandagopal
    Gurudatta Naik
    Guru Sonpavde
    Current Treatment Options in Oncology, 2018, 19
  • [28] Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions
    Zibelman, Matthew
    Ghatalia, Pooja
    Geynisman, Daniel M.
    Plimack, Elizabeth R.
    IMMUNOTHERAPY, 2016, 8 (07) : 785 - 798
  • [29] Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions
    Hussein Merza
    Marijo Bilusic
    Current Oncology Reports, 2017, 19
  • [30] Biomarkers in advanced renal cell carcinoma: current practice and future directions
    Wong, Vivian
    Goodstein, Taylor
    Montenegro, Gabriela Bravo
    Srinivasan, Ramaprasad
    Singer, Eric A.
    CURRENT OPINION IN ONCOLOGY, 2025, 37 (03) : 274 - 282